633 Discovery of HDM2021 as a highly potent CBL-B inhibitor for cancer treatment

Shulun Chen, Min Chen, E Jingwen, Xi Yang, Xinyu Dai, Z Xia, Mengting Zhao, Yunfei Zheng, Dongzhou LiuRegular 2025 · DOI

Introduction

While the advent of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis has transformed oncology, a significant proportion of patients exhibit primary or acquired resistance. This therapeutic gap has driven research into alternative mechanisms of immune evasion. One such mechanism involves intracellular "brakes" that limit the activation of cytotoxic immune cells. Among these, CBL-B (Casitas B-lineage Lymphoma proto-oncogene B), an E3 ubiquitin ligase, has emerged as a critical gatekeeper. By acting as a negative regulator within T cells and Natural Killer (NK) cells, CBL-B prevents over-activation but also inadvertently allows tumors to escape immune surveillance.

This paper details the discovery and preclinical validation of HDM2021, a highly potent, small-molecule inhibitor of CBL-B designed to "release the brakes" on the immune system from within the cell.

AI-Integrated Drug Design (AIDD) Methodology

The development of HDM2021 utilized a sophisticated Artificial Intelligence Drug Design (AIDD) platform to accelerate the transition from initial chemical scaffolds to a clinical-grade lead candidate. The workflow integrated several advanced computational and experimental techniques:

  • Scaffold-Hopping and Core Design: Researchers explored multiple chemical series to identify optimal molecular skeletons for CBL-B binding.
  • Integrated AI Stack: The team employed a combination of machine learning, molecular docking, and Quantitative Structure-Activity Relationship (QSAR) modeling.
  • Free Energy Perturbation (FEP): To achieve high precision in predicting binding affinity, the researchers used FEP calculations, a computationally intensive method that simulates the energy changes associated with molecular modifications.
  • Validation Pipeline: Over 100 candidate compounds were synthesized and screened using TR-FRET biochemical assays and functional human T/NK cell assays to measure immune activation, specifically focusing on interferon-gamma (IFN-\gamma) secretion.

Key Insights and Biochemical Potency

HDM2021 was identified as the lead candidate due to its exceptional potency and functional profile. Unlike traditional immunotherapies that target extracellular receptors, HDM2021 operates intracellularly, potentially bypassing resistance mechanisms that render surface-level checkpoint inhibitors ineffective.

Biochemical Performance

In biochemical assays, HDM2021 demonstrated a CBL-B displacement $IC_{50}$ of less than 5 nM. This high level of potency is essential for small-molecule inhibitors to ensure therapeutic efficacy while minimizing the risk of off-target toxicity associated with higher dosages.

Functional Immune Activation

The compound showed a profound ability to re-energize immune cells in vitro:

  • T Cells: HDM2021 induced a 38-fold increase in IFN-\gamma secretion, suggesting a powerful restoration of the adaptive immune response.
  • NK Cells: The compound also boosted the innate immune response, showing an approximate 3-fold increase in IFN-\gamma secretion.

Preclinical Efficacy and Synergetic Effects

To evaluate the therapeutic potential of HDM2021 in a complex biological environment, the researchers utilized the CT26 syngeneic tumor mouse model. This model is a standard benchmark for assessing how immunotherapies interact with a functional immune system.

As a monotherapy, HDM2021 showed promising activity, but its most significant impact was observed in combination with standard-of-care anti-PD1 antibodies. The combination therapy achieved a Tumor Growth Inhibition (TGI) of over 80%. This synergistic effect indicates that targeting both intracellular (CBL-B) and extracellular (PD-1) checkpoints simultaneously provides a more comprehensive attack on tumor-induced immunosuppression.

Conclusion and Future Directions

HDM2021 represents a promising new class of intracellular immunotherapy. By successfully inhibiting CBL-B with high potency, the compound effectively restores the activity of T and NK cells, particularly when used in conjunction with existing checkpoint inhibitors.

While the results are compelling, the specific chemical structure of HDM2021 remains proprietary. Future research will need to expand testing to "cold" tumors—those typically resistant to immunotherapy—to determine if CBL-B inhibition can turn non-responsive environments into targets for the immune system. Currently, HDM2021 has entered IND-enabling studies, marking the final stage of preclinical safety and toxicity testing before potential human clinical trials.

Summary updated

BibTeX
@inproceedings{chen2025discovery,
  author = {Shulun Chen and Min Chen and E Jingwen and Xi Yang and Xinyu Dai and Z Xia and Mengting Zhao and Yunfei Zheng and Dongzhou Liu},
  title = {{633 Discovery of HDM2021 as a highly potent CBL-B inhibitor for cancer treatment}},
  booktitle = {Regular},
  year = {2025},
  doi = {10.1136/jitc-2025-sitc2025.0633},
}
Figure